{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 101 of 169', 'Consequently, an imputation model with only region and baseline effects (IGA as a factor and', 'EASI as a covariate [only for EASI75]) will be applied for discontinued subjects. Some', 'factors may have to be omitted, depending on the observed data, e.g. if retrieved subjects only', 'come from one region or if they all have the same baseline severity.', 'The imputed datasets will be analysed in the same way as specified for the primary analysis of', 'the secondary estimand.', 'Sensitivity analyses for the tertiary estimand', 'Rather than imputing Week 16 data as described in the primary analysis of the tertiary', 'estimand, missing observations will be imputed as \"non-responders\\'. The assumption reflects', 'that discontinued subjects without retrieved data at Week 16 are more likely to be non-', 'responders than resembling discontinued subjects with retrieved data at Week 16.', '12.3.5.2 Analysis of secondary endpoints', 'The 3 secondary endpoints evaluate the impact of 16 weeks of treatment on (i) severity and', 'extent of AD, (ii) itch, and (iii) HRQoL. The corresponding endpoints are (i) the change from', 'baseline to Week 16 in SCORAD, (ii) reduction (Y/N) of Worst Daily Pruritus NRS average', \"score for the past week (hereinafter 'Worst Daily Pruritus NRS weekly average') of at least 4\", 'from baseline to Week 16, and (iii) change from baseline to Week 16 in DLQI score.', 'Subject-reported worst daily itch over the last week prior to baseline will be used to calculate', 'the baseline itch (see also inclusion criterion no. 9).', 'Reduction of Worst Daily Pruritus NRS weekly average of at least 4 is a binary endpoint, and', 'it will be analysed as described for the primary endpoint EASI75 using all three estimands', 'with the modification of the ANCOVA imputation model that reduction of Worst Daily', 'Pruritus NRS weekly average replaces EASI where preceding values are used as covariates.', 'The change from baseline to Week 16 in SCORAD and DLQI, respectively, are continuous', 'endpoints and will be analysed as described below.', 'All analyses will be based on the full analysis set unless otherwise specified.', '12.3.5.2.1 Primary estimand for the continuous secondary endpoints:', '\"hypothetical\\'', 'The primary estimand for the continuous secondary endpoints will be:', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 102 of 169', 'Treatment difference in change from baseline to Week 16 in SCORAD and DLQI,', 'respectively, if all subjects adhered to the treatment regimen in the sense that they did', 'not discontinue IMP permanently and no rescue medication was made available before', 'Week 16.', 'The primary estimand assesses the expected benefit when adhering to the treatment regimen', 'tralokinumab with no rescue medication as compared to a treatment regimen with placebo', 'with no rescue medication.', 'Primary analysis of the primary estimand (continuous secondary endpoints)', 'Data collected after permanent discontinuation of IMP or after initiation of rescue medication', 'will not be included in the analysis.', 'The endpoints will be analysed using a repeated measurements model on the post baseline', 'responses up to Week 16 with an unstructured covariance matrix, Kenward-Roger', 'approximation to estimate denominator degrees of freedom, and the mean modelled as', 'follows (shown for change from baseline in SCORAD):', 'Change from baseline in SCORAD', '=', 'treatment X visit + baseline SCORAD X visit + region + baseline IGA', 'This model assumes that data is missing at random within each treatment arm. The estimates', 'will be presented with nominal p-values and 95% CI at each visit. The primary comparison', 'between tralokinumab and placebo will be at Week 16.', 'Sensitivity analysis for the primary estimand (continuous secondary endpoints)', 'Rather than assuming that observations are missing at random within each treatment arm it is', 'assumed that missing data from subjects who discontinue treatment/receive rescue medication', 'in the tralokinumab arm will resemble data from subjects from the placebo arm who do not', 'discontinue treatment/receive rescue medication. Imputation of missing data at Week 16 will', 'be done using a pattern mixture model where missing data in the tralokinumab arm as well as', 'the placebo arm will be imputed from the placebo arm (using a so-called copy-reference', 'approach). The procedure for the change from baseline in SCORAD at Week 16 is described', 'below. The same procedure will be applied for the DLQI endpoint.', '1. Intermittent missing values will be imputed in each group using a Markov Chain', 'Monte Carlo method to obtain a monotone missing data pattern and 100 copies of the', 'dataset will be generated (seed=29099725).', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}